Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny (NASDAQ: PGNY) is a leading fertility benefits management company that partners with self-insured employers and health plans to offer comprehensive family-building solutions. The company’s approach combines clinical expertise, data analytics and patient support to guide members through the complexities of fertility treatment. Progyny’s core services include in vitro fertilization (IVF), genetic testing, fertility preservation, egg freezing, and fertility-related medications.

Central to Progyny’s offering is its proprietary Smart Cycle® benefit design, which coordinates all aspects of the treatment process, from diagnostics to follow-up care. By working with a curated network of fertility specialists and clinics, Progyny seeks to improve clinical outcomes while controlling cost trends. In addition to medical treatments, Progyny provides member support through dedicated patient care advocates who offer personalized education, logistics coordination and emotional guidance throughout the treatment journey.

Since its founding in 2016, Progyny has expanded its reach across the United States, serving employees in multiple industries including technology, finance, professional services and healthcare. The company’s platform is built to scale with the needs of large and mid-sized organizations, and it has secured partnerships with dozens of Fortune 500 companies. Progyny leverages proprietary analytics to monitor program performance, optimize benefit design and track key success metrics such as live birth rates and overall member satisfaction.

Progyny’s leadership team is led by Chief Executive Officer David Schlanger, who brings extensive experience in healthcare strategy and benefits management. Under his direction, Progyny completed its initial public offering in 2019, further positioning the company for growth in the evolving fertility and family-building market. With a focus on innovation and patient-centric care, Progyny continues to refine its service offerings and expand its role as a strategic partner to employers seeking to support employees’ reproductive health and wellness.

Key Stats

• Today's Range: $23.05 to $23.60
• 50-Day Range: $20.52 to $24.27
• 52-Week Range: $13.39 to $30.42
• Volume: 739,927 shs
• Average Volume: 1.72 million shs
• Market Capitalization: $1.99 billion
• P/E Ratio: 40.72
• Dividend Yield: N/A
• Price Target: $24.09
• Consensus Rating: Moderate Buy

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 22% of companies evaluated by MarketBeat, and ranked 851st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Progyny has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.33%

Earnings Growth

Earnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 40.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 40.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.30% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Progyny has recently increased by 10.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.30% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Progyny has recently increased by 10.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Progyny has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Progyny this week, compared to 8 articles on an average week.

Search Interest

6 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,037.00 in company stock.

Percentage Held by Insiders

Only 9.40% of the stock of Progyny is held by insiders.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PGNY Stock Analysis - Frequently Asked Questions

How have PGNY shares performed this year?

Progyny's stock was trading at $17.25 at the beginning of the year. Since then, PGNY stock has increased by 34.6% and is now trading at $23.21.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings results on Thursday, May, 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.28. Progyny's revenue for the quarter was up 16.5% on a year-over-year basis.
Read the conference call transcript.

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Top institutional investors of Progyny include Leibman Financial Services Inc. (0.05%) and Central Pacific Bank Trust Division (0.01%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 310
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Progyny: $24.09
• High Price Target: $31.00
• Low Price Target: $17.00
• Potential Upside/Downside: +3.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.57
• Trailing P/E Ratio: 40.72
• Forward P/E Ratio: 38.68
• P/E Growth: 2.39
• Net Income: $54.34 million
• Net Margins: 4.33%
• Pretax Margin: 7.19%
• Return on Equity: 10.90%
• Return on Assets: 7.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: $1.21 billion
• Price / Sales: 1.64
• Cash Flow: $0.35 per share
• Price / Cash Flow: 67.26
• Book Value: $4.96 per share
• Price / Book: 4.68

Miscellaneous

• Outstanding Shares: 85,718,000
• Free Float: 77,661,000
• Market Cap: $1.99 billion
• Optionable: Optionable
• Beta: 1.31